Kura Oncology KURA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $18.27M+29.5% | $17.34M+28.7% | $20.75M+54.0% | $15.29M+13.5% | $14.11M+4.7% | ||
| $262K— | —— | —— | —— | —— | ||
| $18M— | —— | —— | —— | —— | ||
| 98.6%— | —— | —— | —— | —— | ||
| $65.26M+16.6% | $64.41M+23.2% | $67.91M+62.8% | $62.79M+58.0% | $55.97M+54.3% | ||
| $31.56M+38.2% | —— | —— | —— | $22.84M+18.5% | ||
| $97.08M+23.2% | —— | —— | —— | $78.81M— | ||
| -$78.82M-21.8% | -$86.27M-284% | -$80M-33.6% | -$72.67M-28.8% | -$64.7M-18.8% | ||
| -431.5%+27.1pp | -497.6%-331pp | -385.5%+59.0pp | -475.3%-56.6pp | -458.6%-54.4pp | ||
| $336K-12.0% | $346K-14.1% | $393K-4.6% | $391K-3.7% | $382K-4.0% | ||
| $5.83M-26.1% | $5.69M+0.5% | $6.27M+6.5% | $6.94M+16.1% | $7.88M+48.0% | ||
| $5.49M-26.8% | $5.34M+1.6% | $5.88M+7.3% | $6.54M+17.5% | $7.5M+52.2% | ||
| -$73.33M-28.2% | -$80.93M-371% | -$74.12M-36.2% | -$66.12M-30.1% | -$57.2M-15.5% | ||
| $8K-96.5% | $71K-85.9% | —— | —— | $226K-55.2% | ||
| -$73.33M-27.7% | -$81M-321% | -$74.12M-36.2% | -$66.12M-30.1% | -$57.43M-16.0% | ||
| -401.5%+5.6pp | -467.2%-325pp | -357.2%+46.7pp | -432.5%-55.1pp | -407.1%-39.4pp | ||
| -$0.83-25.8% | -$0.92-318% | -$0.85-34.9% | -$0.75-27.1% | -$0.66-11.9% | ||
| -$0.83-25.8% | -$0.92-318% | -$0.85-34.9% | -$0.75-27.1% | -$0.66-11.9% | ||
| 88.6M+1.4% | 87.7M+1.8% | 87.6M+0.8% | 87.6M+1.1% | 87.4M+4.2% | ||
| 88.6M+1.4% | 87.7M+1.8% | 87.6M+0.8% | 87.6M+1.1% | 87.4M+4.2% | ||
| —— | $14.25K— | $14.25K— | $14.25K— | $14.25K— | ||
| -$74.74M-30.6% | -$80.89M-313% | -$73.91M-39.9% | -$66.39M-31.5% | -$57.22M-16.6% | ||
| $5.83M-26.1% | $5.69M+0.5% | $6.27M+6.5% | $6.94M+16.1% | $7.88M+48.0% | ||
| -$1.4M-769% | —— | $207K-86.9% | -$263K-175% | $210K— | ||
| $18.27M+29.5% | $17.34M+28.7% | $20.75M+54.0% | $15.29M+13.5% | $14.11M+4.7% | ||
| -$78.82M-21.8% | -$86.27M-284% | -$80M-33.6% | -$72.67M-28.8% | -$64.7M-18.8% | ||
| -$78.46M-21.7% | -$85.87M-286% | -$79.83M-33.8% | -$72.44M-28.9% | -$64.46M-18.9% | ||
| -$78.46M-21.7% | -$85.87M-286% | -$79.83M-33.8% | -$72.44M-28.9% | -$64.46M-18.9% | ||
| -429.6%+27.3pp | -495.3%-330pp | -384.7%+58.3pp | -473.8%-56.6pp | -456.9%-54.4pp | ||
| -$78.82M-21.8% | -$86.27M-284% | -$80M-33.6% | -$72.67M-28.8% | -$64.7M-18.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Kura Oncology's revenue?
- Kura Oncology (KURA) generated $71.6M in revenue over the trailing twelve months, up 31.4% year over year.
- Is Kura Oncology profitable?
- Kura Oncology is not currently profitable: it reported a net loss of $294.6M over the trailing twelve months, a -411.2% net margin.
- What is Kura Oncology's earnings per share?
- Kura Oncology's diluted EPS over the trailing twelve months is $-3.35.
- Where does Kura Oncology's income statement data come from?
- Every line is extracted from Kura Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
